Development asset linked to Actuate Therapeutics in public FDA and regional records. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
pharma · Pancreatic Adenocarcinoma · Cancer · ACTU
Actuate Therapeutics
ACTUATE THERAPEUTICS, INC.
Actuate Therapeutics drug portfolio — 11 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
1751 River Run, Suite 400, Fort Worth, Texas 76107, US HQ
2015 Founded
16 Employees
Public company Type
ACTU · NYSE Ticker
Company details
- Status
- Public
- HQ
- 1751 River Run, Suite 400, Fort Worth, Texas 76107, US
- Founded
- 2015
- Employees
- 16
- Programs
- 12
- Drugs
- 11
- Patents
- 7
Actuate Therapeutics pipeline
Portfolio lens on 11 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Actuate Therapeutics drug portfolio — 11 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Mechanism: DNA polymerase (alpha/delta/epsilon) inhibitor.
- Mechanism
- DNA polymerase (alpha/delta/epsilon) inhibitor
-
Development asset linked to Actuate Therapeutics in public FDA and regional records.
-
Development asset linked to Actuate Therapeutics in public FDA and regional records.
-
Development asset linked to Actuate Therapeutics in public FDA and regional records. Molecular target: Progesterone receptor.
- Target
- Progesterone receptor
- Mechanism
- Progesterone receptor agonist
-
US regulatory status: approved. Molecular target: Progesterone receptor.
- Target
- Progesterone receptor
- Mechanism
- Progesterone receptor agonist
-
Development asset linked to Actuate Therapeutics in public FDA and regional records.
-
retifanlimab
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Actuate Therapeutics's portfolio. Molecular target: Programmed cell death protein 1.
- Target
- Programmed cell death protein 1
- Mechanism
- Programmed cell death protein 1 antagonist
-
US regulatory status: approved. Molecular target: Programmed cell death protein 1.
- Target
- Programmed cell death protein 1
- Mechanism
- Programmed cell death protein 1 antagonist
-
ruxolitinib
Dermatologicals (D11)US regulatory status: approved. Mechanism: Tyrosine-protein kinase JAK2 inhibitor.
- Mechanism
- Tyrosine-protein kinase JAK2 inhibitor
-
Development asset linked to Actuate Therapeutics in public FDA and regional records.